Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.19 CAD
Change Today +0.005 / 2.78%
Volume 2.5M
As of 3:59 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

sirona biochem corp (SBM) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/14 - C$0.20
52 Week Low
07/18/14 - C$0.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SIRONA BIOCHEM CORP (SBM)

Related News

No related news articles were found.

sirona biochem corp (SBM) Related Businessweek News

No Related Businessweek News Found

sirona biochem corp (SBM) Details

Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada. The company develops programs in three areas, including diabetes and cancer therapeutics; anti-aging and depigmenting agent in cosmeceuticals; biological ingredients, such as inducers and adjuvants for biological development. It develops a sodium glucose co-transporter inhibitor for the treatment of Type 2 diabetes; and a cancer vaccine antigen. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Founded in 2006

sirona biochem corp (SBM) Top Compensated Officers

Founder, Chairman of the Board, Interim Chief...
Total Annual Compensation: C$95.0K
Chief Financial Officer and Director
Total Annual Compensation: C$102.0K
Compensation as of Fiscal Year 2013.

sirona biochem corp (SBM) Key Developments

Sirona Biochem Announces Positive Preclinical Toxicology Results for its SGLT2 Inhibitor

Sirona Biochem Corp. announced that Wanbang Biopharmaceuticals has successfully completed the toxicology study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor, SBM-TFC-039, for the treatment of Type 2 diabetes. In the study, SBM-TFC-039 was orally administered to Sprague Dawley (SD) rats for 14 days to evaluate safety and simultaneously observe toxicokinetics. Dosing of SBM-TFC-039 was either 0, 100, 300 or 800 milligrams per kilogram per day (mg/kg/day) as well as 300 mg/kg/day of the reference drug Canagliflozin. The results of the study demonstrated that the maximum tolerated dose (MTD) of SBM-TFC-039 was greater than 800 mg/kg/day, which was significantly greater than the 300 mg/kg/day of the Canagliflozin reference. There was no mortality in the groups treated with SBM-TFC-039 and the histopathology showed no visual abnormalities. The reference drug Canagliflozin is Johnson and Johnson's SGLT2 inhibitor for type 2 diabetes. It was the first SGLT2 inhibitor launched and it has been on the market in many countries including the United States since 2013. The completion of this test will trigger a milestone payment to Sirona from Wanbang Biopharmaceuticals as part of the $9.5 million in upfront and milestone payments.

Sirona Biochem Appoints Martin Gleave to its Board of Directors

Sirona Biochem Corp. announced the appointment of Dr. Martin Gleave to its Board of Directors. Dr. Gleave holds numerous leadership positions in research and academia. He is currently distinguished Professor and Vice Chair of the Department of Urologic Sciences at UBC, and Director at the Vancouver Prostate Centre (VPC).

Sirona Reports Earnings Results for the Fourth Quarter of 2014

Sirona reported earnings results for the fourth quarter of 2014. For the quarter, the company reported total revenue of $290.0 million, increasing 4% compared to $278.6 million in the fourth quarter of 2013. Gross margin increased to 55.1% from 51.4% in the fourth quarter of 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBM:CN C$0.19 CAD +0.005

SBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBM.
View Industry Companies

Industry Analysis


Industry Average

Valuation SBM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 97.3x
Price/Book 11.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 95.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIRONA BIOCHEM CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at